<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2734">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681079</url>
  </required_header>
  <id_info>
    <org_study_id>0192</org_study_id>
    <nct_id>NCT04681079</nct_id>
  </id_info>
  <brief_title>Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19</brief_title>
  <official_title>A 2-Period, Crossover Study to Assess the Impact of Nebulizer With Filtered Mouthpiece vs MDI With Spacer on Viral Load in Rooms of Subjects With Mild to Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, 2-period crossover, single-center, open-label study for viral sample&#xD;
      collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and&#xD;
      surface samplers will be used to assess viral loads in rooms of subjects with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational Study Model = Other [non-treatment; impact on external location (rooms and&#xD;
      surfaces)]&#xD;
&#xD;
      Time Perspective = Other [viral load samples taken at various time points after nebulization&#xD;
      or MDI administered]&#xD;
&#xD;
      Sampling Method = Non-probability sample [to be described by study team]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Load</measure>
    <time_frame>Baseline, Day 1</time_frame>
    <description>Change in viral load from baseline at each sample point (room air and surfaces). This outcome measure is listed as exploratory in the protocol.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Crossover Sequence 1</arm_group_label>
    <description>Subjects randomized to receive commercially available albuterol sulfate via MDI with spacer first, followed by albuterol sulfate via nebulizer with filtered mouthpiece.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover Sequence 2</arm_group_label>
    <description>Subjects randomized to receive commercially available albuterol sulfate via nebulizer with filtered mouthpiece first, followed by albuterol sulfate via MDI with spacer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol sulfate (MDI)</intervention_name>
    <description>albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer</description>
    <arm_group_label>Crossover Sequence 1</arm_group_label>
    <arm_group_label>Crossover Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol sulfate (nebulizer)</intervention_name>
    <description>albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece</description>
    <arm_group_label>Crossover Sequence 1</arm_group_label>
    <arm_group_label>Crossover Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with mild to moderate COVID-19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent, either themselves or via legally&#xD;
             acceptable representative, prior to undergoing study procedures&#xD;
&#xD;
          2. Willing and able to comply with study-related procedures/assessments&#xD;
&#xD;
          3. Adults over 18 years of age&#xD;
&#xD;
          4. COVID-19 infection as confirmed by PCR from nasopharyngeal, oropharyngeal swabs and/or&#xD;
             saliva specimen taken within the previous 5 days&#xD;
&#xD;
          5. Being treated with albuterol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects currently receiving mechanical ventilation or noninvasive positive-pressure&#xD;
             ventilation, or subjects who, in the opinion of the investigator, will require&#xD;
             ventilatory support (i.e., mechanical ventilation or noninvasive positive-pressure&#xD;
             ventilation) within the next 12 hours Note: Signs of impending need for ventilatory&#xD;
             support include pronounced hypoxia despite supplemental oxygen &gt;6 L/min, prolonged&#xD;
             respiratory rate (i.e., &gt;30 breaths per minute), signs of respiratory muscle fatigue,&#xD;
             or paradoxical diaphragm.&#xD;
&#xD;
          2. Presence of significant comorbidity that, in the opinion of the investigator, makes&#xD;
             the subject unsuitable for participation in the study&#xD;
&#xD;
          3. Known or suspected hypersensitivity to albuterol, history of paradoxical bronchospasm,&#xD;
             or significant cough response to albuterol&#xD;
&#xD;
          4. Participating in other clinical trials related to COVID-19 thought to interfere with&#xD;
             study interpretation (e.g., antivirals or antibodies that might change the viral load&#xD;
             over the course of a day)&#xD;
&#xD;
          5. Active or incompletely treated pulmonary infections, such as tuberculosis (or known&#xD;
             history of nontuberculosis mycobacterium) over past 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theravance Biopharma Call Center</last_name>
    <phone>1-855-633-8479</phone>
    <email>medinfo@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Theravance Biopharma Call Center</last_name>
      <phone>855-633-8479</phone>
      <email>medinfo@theravance.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nebulizer</keyword>
  <keyword>MDI</keyword>
  <keyword>Meter Dosed Inhaler</keyword>
  <keyword>Filter</keyword>
  <keyword>Spacer</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus disease 2019</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Aerosol</keyword>
  <keyword>Viral transmission</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

